Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
GLP-1 treatment benefits patients on statins and with varying LDL levels.
Read More »Liraglutide Lowers Risk of Cardiovascular Events In Type 2 Diabetes
GLP-1/GIP Drug Shows Promise in Reducing A1c and Reducing Weight
New combination drug has better efficacy in glucose control and weight loss than when taken separately.
Read More »Oral Semaglutide Shows Promise in HbA1c Reduction and Weight Loss
First oral GLP-1 agonist undergoing Phase 3 trials shows significant benefits managing type 2 diabetes.
Read More »Albiglutide’s Effect on Cardiovascular Outcomes in People with Type 2 Diabetes
Study looks at convenient once-weekly GLP-1 that can reduce chances of heart attacks and strokes.
Read More »GLP-1 Agonist Medications Chart
This GLP-1 Agonist Medications Chart outlines the latest GLP-1 medications approved by the FDA for diabetes treatment and the differences and similarities between them. Print out this chart and post in your office as a handy reference for your staff and patients alike. The chart is in PDF format. Use this link to download: GLP-1 Agonist Medications Chart
Read More »Comparison of Semaglutide versus Liraglutide for Weight Loss in Patients with Obesity
Researchers study efficacy and safety of GLP-1 inhibitors on weight loss.
Read More »Semaglutide May Foster Significant Weight Loss in Patients with Obesity
When combined with diet and exercise, GLP-1 medication showed significant weight loss compared to liraglutide and placebo, a new study finds.
Read More »GLP-1 Agonists Do Not Increase Risk for Diabetic Retinopathy
New findings compare treatment with patients taking two or more glucose-lowering agents.
Read More »Liraglutide Lowers Risk for Amputation in Patients with Type 2 Diabetes and CV Risk
Investigators find patients treated with GLP-1 drug had significantly lower number of amputations compared to placebo group.
Read More »Poster Summaries of Interest at the 78th ADA Scientific Sessions
Key ADA poster summaries include liraglutide in type 1 diabetes, oral semaglutide, bottled water's association with type 2 diabetes, & SGLT-2 combo LIK066.
Read More »